We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

The clinical-stage biopharmaceutical firm, Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, develops novel ...

Viking Therapeutics ( (VKTX) ) has provided an announcement.

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Shares of San Diego, USA-based Viking Therapeutics tumbled 43% to $23.50 by mid-morning after the company released mid-stage ...